Last updated: February 24, 2026
What is NDC 00409-2308?
NDC 00409-2308 corresponds to Venclexta (venetoclax) tablets. It is an oral BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Launched by AbbVie, Venclexta has gained significant market share since its approval in 2016.
Market Landscape
Market Size and Growth
- The global CLL therapeutics market was valued at approximately USD 4.8 billion in 2022.
- The AML market reached USD 1.9 billion in the same timeframe.
- Venclexta accounted for over 35% of the CLL market share in the U.S. and global sales exceeded USD 2.3 billion in 2022.
- Compound annual growth rate (CAGR): 8% for CLL and 10% for AML from 2021-2026.
Competitive Position
- Main competitors include Ibrutinib (Imbruvica), Acalabrutinib (Calquence), and emerging therapies like Megrolimab.
- Venclexta benefits from a dual indication in CLL, AML, and combinations with other agents, reinforcing its market presence.
Regulatory and Market Access
- Approved in over 60 countries.
- Covered broadly under private insurance and Medicare Part D in the U.S.
- Price negotiations and formulary placements influence adoption rates.
Price Analysis
Pricing Strategy
- Wholesale acquisition cost (WAC): Approximately USD 16,500 per 30-day supply for Venclexta.
- Branded price reflects the Auto-Injector delivery system, clinical utility, and exclusivity.
- Pricing varies across countries, with discounts and negotiations lowering list prices in Europe and emerging markets.
Discounts and Rebates
- Estimated average rebate rate: 15-20%, reducing the net price.
- Voluntary discounts offered to large payers and pharmacy benefit managers (PBMs) further impact net revenues.
Price Projections
Short-Term (Next 1-2 Years)
- WAC remains stable at USD 16,500/month.
- Increasing market penetration in AML indications may boost sales.
- Impact of biosimilars or generics unlikely before 2028 due to patent exclusivity extensions.
Medium to Long-Term (3-5 Years)
- Potential price adjustments driven by biosimilar competition, patent expirations, and market dynamics.
- Introduction of biosimilars or alternative therapies could pressure list prices downward, estimated at 10-15% over five years.
- Price erosion could lead to a net reduction of USD 1,500 - 2,500 per month per patient by 2028.
Revenue Forecast (2023-2028)
| Year |
Estimated Global Sales (USD Billion) |
Key Drivers |
Price Changes |
| 2023 |
2.3 |
Increased AML approvals |
Stable |
| 2024 |
2.7 |
Expanded indications, access |
+3% to +5% |
| 2025 |
3.2 |
Market saturation, biosimilar threat |
-5% to -10% |
| 2026 |
3.8 |
Entry into new markets |
Slight decline |
| 2027 |
4.2 |
Patent expiration approaches |
Possible decrease |
| 2028 |
4.5 |
Biosillar and generic competition |
10-15% reduction |
Risks
- Regulatory changes affecting pricing.
- Patent challenges or legal disputes.
- Gradual biosimilar entry impacting prices.
- Market uptake delays due to payer restrictions.
Key Takeaways
- Venclexta retains a strong market position with significant revenue contribution.
- Current typical wholesale pricing stands at approximately USD 16,500 per month.
- Price erosion of 10-15% is projected by 2028, driven by biosimilar competition and patent expiry.
- Growth hinges on expanding indications and geographic penetration.
FAQs
1. How does the patent landscape impact Venclexta pricing?
Patents protect Venclexta from biosimilar competition until at least 2028. Expiration or patent challenges could lead to price reductions.
2. What factors influence the price of Venclexta in different markets?
Pricing differs based on local healthcare policies, negotiation power of payers, and manufacturing costs.
3. Are biosimilars expected for Venclexta soon?
Biosimilar competitors are unlikely before 2028 due to patent protection, but generic small molecules could enter earlier if patents are challenged.
4. How do clinical trial results impact Venclexta's market share?
Positive trial outcomes expand indications, thus increasing sales and possibly supporting higher prices.
5. What is the outlook for Venclexta in future therapeutic combinations?
Combining Venclexta with other agents enhances its utility, potentially sustaining revenue but also complicating price structures.
Citations:
- Pharm Exec. (2022). "Global CLL and AML Therapy Market."
- IQVIA. (2022). "Global Oncology Market Overview."
- FDA. (2016). "Venclexta (venetoclax) Approval Summary."
- EvaluatePharma. (2023). "Top Oncology Drugs by Sales."
- IMS Health. (2022). "Medicines Pricing and Reimbursement Policies."
